Matrix-assisted laser desorption/ionization

Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification

Retrieved on: 
Thursday, August 24, 2023
Research, Technology, Professional Services, Software, Biotechnology, Data Analytics, Health, Data Management, Science, Oncology, Mayo Clinic, IVDR, Serum, Multiple myeloma, Immunoglobulin M, Bone marrow, Immunoassay, GAM, Thermo Fisher Scientific, Immunoglobulin A, Binding site, The Advanced Visualizer, HIV disease progression rates, Acquisition, Patient, Laboratory, Immunoglobulin G, Diagnosis, Matrix-assisted laser desorption/ionization, World Health Organization, Medical device, Medical imaging, Fine chemical

Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*.
  • The EXENT Solution is now commercially available in the following countries: Belgium, France, Germany, Italy, the Netherlands, Spain and United Kingdom.
  • “The EXENT Solution represents a significant breakthrough in innovation for the detection and monitoring of monoclonal immunoglobulins,” said Dr. Stephen Harding, Chief Scientific Officer, Protein Diagnostics, Thermo Fisher.
  • Earlier this year, Thermo Fisher Scientific completed the acquisition of The Binding Site, adding protein diagnostics solutions, including diagnosis and monitoring for monoclonal gammopathies, to its specialty diagnostics portfolio.

BioFlyte Launches First-of-Its-Kind Biothreat Surveillance Pilot Program at Pittsburgh International Airport

Retrieved on: 
Tuesday, August 22, 2023
Hardware, Other Defense, Contracts, Security, Technology, Nanotechnology, Transportation, General Health, Travel, Defense, Air, Transport, Biotechnology, Science, Other Science, Health, PIT, Partnership, Pittsburgh International Airport, Atmosphere, Aviation, Matrix-assisted laser desorption/ionization, Multimedia, HVAC, Collection, Algorithm, Bacteria, Robotics, Virus, Safety, MALDI, Risk management

BioFlyte , a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection and identification solutions, today announced a comprehensive pilot program with Pittsburgh International Airport (PIT) to utilize its fieldable mass spectrometer to add a new layer of safety for the airport.

Key Points: 
  • BioFlyte , a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection and identification solutions, today announced a comprehensive pilot program with Pittsburgh International Airport (PIT) to utilize its fieldable mass spectrometer to add a new layer of safety for the airport.
  • As a part of this pilot program, one of BioFlyte’s modules is stationed within the airport’s HVAC system to provide continuous, autonomous surveillance of the air moving through the terminals.
  • “This is the first time a biothreat surveillance technology of this caliber has been operationally introduced into this type of complex critical infrastructure,” said Todd Sickles, CEO, BioFlyte.
  • We are a safer, better airport with them onboard.”
    To learn more about this pilot program and to watch the BioFlyte team demo the technology, see the feature and video on PIT’s Blue Sky News .

Waters Sets New Standard in High Resolution Mass Spectrometry with SELECT SERIES Multi Reflecting Time-of-Flight Platform

Retrieved on: 
Tuesday, June 8, 2021
Oncology, Medical devices, Health, Research, Science, Biotechnology, Laboratory techniques, Mass spectrometry, Chemistry, Physical sciences, Ion source, Chemical pathology, Clinical pathology, Matrix-assisted laser desorption/ionization, MALDI imaging, Mass Rapid Transit, Waters Corporation, Spectrometer

Waters Corporation (NYSE:WAT) today introduced the Waters SELECT SERIES MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources.

Key Points: 
  • Waters Corporation (NYSE:WAT) today introduced the Waters SELECT SERIES MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources.
  • The SELECT SERIES MRT platform is the basis for the next generation of Waters high-resolution mass spectrometers.
  • The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market todayii.
  • Customer shipments of the SELECT SERIES MRT are expected to begin in the fourth quarter of this year.

Hardy Diagnostics Releases New Mass Spectrometer for Use in Non-Clinical Applications

Retrieved on: 
Friday, April 2, 2021
Mass spectrometry, Biochemistry methods, Ion source, Matrix-assisted laser desorption/ionization, Hardy Diagnostics, Time-of-flight mass spectrometry

SANTA MARIA, Calif., April 2, 2021 /PRNewswire/ --Hardy Diagnostics, in collaboration with Autobio, recently launched the Hardy Diagnostics Matrix-Assisted Laser Desorption/Ionized Time of Flight instrument, otherwise known as

Key Points: 
  • SANTA MARIA, Calif., April 2, 2021 /PRNewswire/ --Hardy Diagnostics, in collaboration with Autobio, recently launched the Hardy Diagnostics Matrix-Assisted Laser Desorption/Ionized Time of Flight instrument, otherwise known as
    MALDI-TOF .
  • This launch is an example of the diversification of Hardy Diagnostics' product portfolio and further development of instrumentation for use in microbiology labs.
  • Jay Hardy, Hardy Diagnostics Chief Executive Officer stated, "We are very excited to add the MALDI Autof MS 1000 to our lineup of instruments to streamline the processes for microbiologists."
  • Hardy Diagnostics has previously introduced automated Gram stain and automated Hematology stain instruments , as well as air sampling , automated serial dilution , and automated plate reading instrumentation .

Global Antimicrobial Resistance Diagnostics Markets, 2021-2024: New Diagnostic Technologies, Beyond Gene Sequencing Under Development to Capture this Growing Market

Retrieved on: 
Thursday, January 28, 2021
Biochemistry methods, Ion source, Matrix-assisted laser desorption/ionization, Curetis

3.2.8 What Happens to the Microbiology Lab?

Key Points: 

3.2.8 What Happens to the Microbiology Lab?
MALDI-TOF - Results in Minutes, not Days.
Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies

Avacta Announces Collaboration Agreement With Bruker

Retrieved on: 
Thursday, January 28, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Biotechnology, Science and technology, Chemistry, Physical sciences, Bruker, Affimer, Biochemistry methods, Matrix-assisted laser desorption/ionization, Billerica, Massachusetts, Assay, Mass spectrometry

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) (NASDAQ: BRKR, Bruker) to evaluate the Affimer-based, bead assisted mass spectrometry (BAMS) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc. (Beverley, MA) (Adeptrix).

Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) (NASDAQ: BRKR, Bruker) to evaluate the Affimer-based, bead assisted mass spectrometry (BAMS) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc. (Beverley, MA) (Adeptrix).
  • Bruker is one of the worlds leading analytical instrumentation companies providing high-performance scientific instruments and high-value analytical and diagnostic solutions to scientists globally.
  • Alastair Smith, Chief Executive Officer of Avacta Group, commented: I am delighted to have established this collaboration agreement with Bruker to further develop the potential for the BAMS COVID-19 test as a clinical IVD.
  • We will be working closely with Bruker on the clinical assessment of the BAMS assay on Brukers MALDI-TOF instruments.

Global Antimicrobial Resistance Diagnostics Market, Strategies, Trends & Forecasts Report 2021-2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 26, 2021
Health, Other Health, Biochemistry methods, Ion source, Matrix-assisted laser desorption/ionization, Curetis

3.2.8 What Happens to the Microbiology Lab?

Key Points: 

3.2.8 What Happens to the Microbiology Lab?
MALDI-TOF - Results in Minutes, not Days.
Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies

Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research

Retrieved on: 
Wednesday, January 6, 2021
Research, Medical devices, Infectious diseases, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Biochemistry methods, Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Immunologic tests, Ion source, Assay, Titration, Mass spectrometry, Matrix-assisted laser desorption/ionization, Immunoassay

The proceeds will go toward accelerating commercialization of multiple BAMS products and establishing custom BAMS assay development service for pharma, clinical, and food-science customers.

Key Points: 
  • The proceeds will go toward accelerating commercialization of multiple BAMS products and establishing custom BAMS assay development service for pharma, clinical, and food-science customers.
  • Adeptrix has recently entered into several research collaborations, leveraging its unique approach, to develop tools for accurate, rapid and easy-to-use COVID-19 diagnostics.
  • Adeptrix BAMS technology is a multiplexed immunoassay platform for targeted analysis of proteins and protein fragments by MALDI-TOF mass spectrometry.
  • Adeptrix will develop and commercialize BAMS assay kits for virology research and clinical diagnostics, both directly and via its strategic partners worldwide sales and marketing teams.

Frontier Diagnostics Initiates Operations Using Imaging Mass Spectrometry for Cancer Detection

Retrieved on: 
Tuesday, December 15, 2020
Instrumental analysis, Mass spectrometry, Ion source, Biochemistry methods, Mass spectrometry imaging, Matrix-assisted laser desorption/ionization, Matrix, MALDI imaging, Iknife

NASHVILLE, Tenn., Dec. 15, 2020 /PRNewswire/ -- Frontier Diagnostics, a cancer diagnostics company, today announced that it has begun developing and validating a clinical assay for melanoma diagnosis, by direct tissue analysis, using matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry.

Key Points: 
  • NASHVILLE, Tenn., Dec. 15, 2020 /PRNewswire/ -- Frontier Diagnostics, a cancer diagnostics company, today announced that it has begun developing and validating a clinical assay for melanoma diagnosis, by direct tissue analysis, using matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry.
  • Frontier Diagnostics also announced that it has purchased assets from New River Labs, LLC, a company that made significant investments in imaging mass spectrometry diagnostics in recent years.
  • Norris and Caprioli, internationally known for pioneering imaging mass spectrometry, are faculty members at Vanderbilt University and direct the National Resource for Imaging Mass Spectrometry.
  • Frontier Diagnostics holds several patents for the use of imaging mass spectrometry in diagnostics.

Shimadzu Scientific Instruments and Front Range Biosciences Partner to Establish a Hemp Science Center of Excellence

Retrieved on: 
Tuesday, August 25, 2020
Physical sciences, Chemistry, Natural sciences, Mass spectrometry, Chromatography, Shimadzu, Matrix-assisted laser desorption/ionization, Time-of-flight mass spectrometry, Liquid chromatography–mass spectrometry, High-performance liquid chromatography, Gas chromatography–mass spectrometry, Time of flight

COLUMBIA, Md., Aug. 25, 2020 /PRNewswire-PRWeb/ --Shimadzu Scientific Instruments (SSI) and Front Range Biosciences (FRB) announced today their partnership to establish a Hemp Science Center of Excellence.

Key Points: 
  • COLUMBIA, Md., Aug. 25, 2020 /PRNewswire-PRWeb/ --Shimadzu Scientific Instruments (SSI) and Front Range Biosciences (FRB) announced today their partnership to establish a Hemp Science Center of Excellence.
  • The FRB Hemp Science Center of Excellence will focus on genetics, biobanking, breeding and analysis utilizing Shimadzu HPLC/UHPLC, LC-MS/MS, GC-MS/MS and MALDI-TOF MS instruments.
  • "Front Range Biosciences is honored to partner with the world-class team at Shimadzu.
  • About Shimadzu Scientific Instruments Inc.
    Shimadzu Scientific Instruments (SSI) is the North American subsidiary of Shimadzu Corporation's Analytical and Measuring Division.